Panel requires stricter safety criteria for blood system trial

11/17/2009 | Forbes

The FDA's Blood Products Advisory Committee has required Cerus to tighten safety parameters for a late-stage study involving its intercept blood system, which inhibits blood-borne pathogens in blood components used for transfusions. The company said it may take a year to finish preparations for the planned trial.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA